BridgeBio Pharma Inc Forecast, price target & analysts
Why the stock moved Beta
BridgeBio Pharma Inc Target price 2025 - Analyst rating & recommendation
BridgeBio Pharma Inc Classifications & Recommendation:
BridgeBio Pharma Inc Price Target
| Target Price | $70.89 |
| Price | $68.11 |
| Potential |
4.08%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target BridgeBio Pharma Inc 2026 .
The average BridgeBio Pharma Inc target price is $70.89.
This is
4.08%
register free of charge
$99.75
46.45%
register free of charge
$42.63
37.41%
register free of charge
|
|
| A rating was issued by 25 analysts: 23 Analysts recommend BridgeBio Pharma Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BridgeBio Pharma Inc stock has an average upside potential 2026 of
4.08%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 221.90 | 495.56 |
| 2,286.02% | 123.33% | |
| EBITDA Margin | -257.45% | -92.70% |
| 95.96% | 63.99% | |
| Net Margin | -241.44% | -138.16% |
| 96.51% | 42.78% |
22 Analysts have issued a sales forecast BridgeBio Pharma Inc 2025 . The average BridgeBio Pharma Inc sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an BridgeBio Pharma Inc EBITDA forecast 2025. The average BridgeBio Pharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 BridgeBio Pharma Inc Analysts have issued a net profit forecast 2025. The average BridgeBio Pharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.88 | -3.55 |
| 27.09% | 23.26% | |
| P/E | negative | |
| EV/Sales | 30.61 |
22 Analysts have issued a BridgeBio Pharma Inc forecast for earnings per share. The average BridgeBio Pharma Inc EPS is
This results in the following potential growth metrics and future valuations:
BridgeBio Pharma Inc...
Current BridgeBio Pharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Nov 11 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 03 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Nov 11 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 03 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 30 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
